Chronic Lymphocytic Leukemia - Opportunity Analysis and Forecasts to 2018, New Report Launched

New Entrants to Boost Chronic Lymphocytic Leukemia Treatment Market Value to $3.3 Billion by 2018

The introduction of several new drugs will accelerate growth in the Chronic Lymphocytic Leukemia (CLL) treatment market, from $1.4 billion in 2013 to $3.3 billion by 2018 across six major markets (6MM: the US, France, Germany, Italy, Spain and the UK), according to a new report from research and consulting firm by Publisher.

The company’s latest report states that this impressive revenue increase, at a Compound Annual Growth Rate (CAGR) of 18.8%, will occur as numerous premium-priced therapies for CLL patients with high unmet needs are set to enter the market during the forecast period.

Publisher’s Senior Analyst covering Oncology, says: “A number of branded drugs, including Gazyva, Imbruvica, idelalisib and IPI-145, will become available over the next four years, with the expanding patient pool receiving greater access to such new treatments. These factors, alongside dose-continuous regimens replacing fixed courses of therapy, will combine to escalate the CLL market’s value.”

Publisher forecasts that Imbruvica and idelalisib, set for launch in the US and EU in 2014, will have total combined sales of $2 billion in 2018, thus capturing more than 60% of the total CLL market by the end of the forecast period.

Senior Analyst explains: “Imbruvica and idelalisib have shown strong efficacy and tolerability in phase II and III trials, which, in correlation with the high level of unmet need in this patient population, will drive the very rapid uptake of both drugs.

“Furthermore, the completion of trials, as well as the results of studies of Imbruvica and idelalisib in the first-line treatment of elderly patients, which are expected by 2016 and 2017 respectively, will contribute towards establishing these two drugs as the most successful branded therapies for CLL.”

“OpportunityAnalyzer: Chronic Lymphocytic Leukemia - Opportunity Analysis and Forecasts to 2018” report provides an overview of Chronic Lymphocytic Leukemia (CLL), including epidemiology, etiology, pathophysiology, clinical staging, symptoms, quality of life and disease management. It focuses on the current treatment landscape, unmet needs, pipeline and commercial opportunity in the CLL market, with coverage of both the first-line and relapsed/refractory settings.

Know more about this report at : http://mrr.cm/ZWf